Kyrillus S Shohdy1, Shaimaa Lasheen2, Loay Kassem2, Omar Abdel-Rahman3. 1. Clinical Oncology Department, Kasr Alainy School of Medicine, Cairo University, Al-Saray St. El-Maniel, 11451, Cairo, Egypt. 2. Clinical Oncology Department, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt. 3. Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Abstract
BACKGROUND: Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors show promising results in metastatic breast cancer. However, an increased incidence of adverse events is remarkable. Among others, gastrointestinal (GI) involvement is of momentous impact on patients and their quality of life. METHODS: Our search included PubMed, ASCO, ESMO and SABCS databases. Randomized phase II/III trials in metastatic breast cancer receiving CDK4/6 inhibitors were identified and considered relevant based on providing a sufficient safety profile on the incidence of adverse GI effects. RESULTS: Of the 999 records initially screened for relevance, 33 articles were found relevant and 4 studies were finally eligible for meta-analysis with a total of 2007 patients. The relative risk (RR) for all-grade nausea was 1.48 [95% confidence interval (CI): 1.12-1.93, p = 0.005], vomiting was 1.74 (95% CI: 1.09-2.76, p = 0.02), decreased appetite was 1.42 (95% CI: 1.07-1.88, p = 0.02), and for diarrhea it was 1.44 (95% CI: 1.19-1.74, p = 0.0002). Meanwhile, the RR for high-grade nausea was 1.10 (95% CI: 0.29-4.13, p = 0.89), vomiting was 1.38 (95% CI: 0.25-7.75, p = 0.72), decreased appetite was 4.00 (95% CI: 0.87-18.37, p = 0.07), and high-grade diarrhea was 1.19 (95% CI: 0.44-3.21, p = 0.73). CONCLUSION: Selective CDK4/6 inhibitors were not associated with higher-grade GI toxicities reflecting a well-tolerated safety profile. Regarding the increase in all-grade GI toxicities, it needs further caution with addition of cytotoxic chemotherapy.
BACKGROUND:Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors show promising results in metastatic breast cancer. However, an increased incidence of adverse events is remarkable. Among others, gastrointestinal (GI) involvement is of momentous impact on patients and their quality of life. METHODS: Our search included PubMed, ASCO, ESMO and SABCS databases. Randomized phase II/III trials in metastatic breast cancer receiving CDK4/6 inhibitors were identified and considered relevant based on providing a sufficient safety profile on the incidence of adverse GI effects. RESULTS: Of the 999 records initially screened for relevance, 33 articles were found relevant and 4 studies were finally eligible for meta-analysis with a total of 2007 patients. The relative risk (RR) for all-grade nausea was 1.48 [95% confidence interval (CI): 1.12-1.93, p = 0.005], vomiting was 1.74 (95% CI: 1.09-2.76, p = 0.02), decreased appetite was 1.42 (95% CI: 1.07-1.88, p = 0.02), and for diarrhea it was 1.44 (95% CI: 1.19-1.74, p = 0.0002). Meanwhile, the RR for high-grade nausea was 1.10 (95% CI: 0.29-4.13, p = 0.89), vomiting was 1.38 (95% CI: 0.25-7.75, p = 0.72), decreased appetite was 4.00 (95% CI: 0.87-18.37, p = 0.07), and high-grade diarrhea was 1.19 (95% CI: 0.44-3.21, p = 0.73). CONCLUSION: Selective CDK4/6 inhibitors were not associated with higher-grade GI toxicities reflecting a well-tolerated safety profile. Regarding the increase in all-grade GI toxicities, it needs further caution with addition of cytotoxic chemotherapy.
Entities:
Keywords:
CDK4/6 inhibitors; breast cancer; gastrointestinal toxicity; palbociclib
Authors: Tien C Ko; Fuming Pan; Hongmiao Sheng; David B Brown; E Aubrey Thompson; R Daniel Beauchamp Journal: World J Surg Date: 2002-04-15 Impact factor: 3.352
Authors: Keith T Flaherty; Patricia M Lorusso; Angela Demichele; Vandana G Abramson; Rachel Courtney; Sophia S Randolph; M Naveed Shaik; Keith D Wilner; Peter J O'Dwyer; Gary K Schwartz Journal: Clin Cancer Res Date: 2011-11-16 Impact factor: 12.531
Authors: Gabriel N Hortobagyi; Salomon M Stemmer; Howard A Burris; Yoon-Sim Yap; Gabe S Sonke; Shani Paluch-Shimon; Mario Campone; Kimberly L Blackwell; Fabrice André; Eric P Winer; Wolfgang Janni; Sunil Verma; Pierfranco Conte; Carlos L Arteaga; David A Cameron; Katarina Petrakova; Lowell L Hart; Cristian Villanueva; Arlene Chan; Erik Jakobsen; Arnd Nusch; Olga Burdaeva; Eva-Maria Grischke; Emilio Alba; Erik Wist; Norbert Marschner; Anne M Favret; Denise Yardley; Thomas Bachelot; Ling-Ming Tseng; Sibel Blau; Fengjuan Xuan; Farida Souami; Michelle Miller; Caroline Germa; Samit Hirawat; Joyce O'Shaughnessy Journal: N Engl J Med Date: 2016-10-07 Impact factor: 91.245
Authors: Richard S Finn; John P Crown; Johannes Ettl; Marcus Schmidt; Igor M Bondarenko; Istvan Lang; Tamas Pinter; Katalin Boer; Ravindranath Patel; Sophia Randolph; Sindy T Kim; Xin Huang; Patrick Schnell; Sashi Nadanaciva; Cynthia Huang Bartlett; Dennis J Slamon Journal: Breast Cancer Res Date: 2016-06-28 Impact factor: 6.466
Authors: Sarah Alexandrou; Sandra Marie George; Christopher John Ormandy; Elgene Lim; Samantha Richelle Oakes; C Elizabeth Caldon Journal: Int J Mol Sci Date: 2019-02-04 Impact factor: 5.923
Authors: Marina Elena Cazzaniga; Romano Danesi; Corrado Girmenia; Pietro Invernizzi; Alessandra Elvevi; Massimo Uguccioni Journal: Breast Cancer Res Treat Date: 2019-05-07 Impact factor: 4.872
Authors: C Louwrens Braal; Elisabeth M Jongbloed; Saskia M Wilting; Ron H J Mathijssen; Stijn L W Koolen; Agnes Jager Journal: Drugs Date: 2020-12-28 Impact factor: 9.546
Authors: Thamer A Alsubi; Mohamed W Attwa; Ahmed H Bakheit; Hany W Darwish; Hatem A Abuelizz; Adnan A Kadi Journal: RSC Adv Date: 2020-06-12 Impact factor: 4.036